Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Business Wire•04/11/2026•16:05 ET
0
Key Highlights
- ➤ECLIPSE 1 topline data expected in the fourth quarter of 2026
- ➤VIR-5500 achieved proof of concept and received FDA Fast Track designation
- ➤Gilead collaboration brings $90 million cash consideration and potential $1.74 billion milestones
- ➤Third-quarter net loss $96.3 million, or $0.57 per share, versus $163.1 million
- ➤Cash, cash equivalents and investments totaled approximately $901.3 million at quarter-end
Expert Statements
Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology
“We are entering an important period for Vir Bio, with meaningful catalysts across both hepatitis delta and oncology. We look forward to reporting topline ECLIPSE 1 data this quarter as we advance our goal to address the significant unmet need for patients with a therapy that can drive hepatitis delta virus to undetectable. In oncology, VIR-5500 achieved proof of concept and received FDA Fast Track designation, supporting our plans with Astellas to advance the program into pivotal trials next year. With momentum across both areas, we believe Vir Bio is well positioned to deliver meaningful value for patients and stakeholders.”
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results
- Topline data from pivotal Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026
Get started
Create a free account to read the full story.